Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

NZ sharemarket enjoys good week with fourth gain
Markets Market close

NZ sharemarket enjoys good week with fourth gain

The S&P/NZX 50 Index closed at 11,938.08, up 64.04 points or 0.54%.

Graham Skellern 03 May 2024
BHP CEO flies to South Africa to push $65.4 billion takeover
Markets

BHP CEO flies to South Africa to push $65.4 billion takeover

The executives have already begun conversations with key stakeholders.

Bloomberg 03 May 2024
Rakon shareholder wants light shed on $400m bid
Markets

Rakon shareholder wants light shed on $400m bid

US giant Skyworks could be Rakon's new owner. One shareholder wants it to confirm.